反応式
[C:1]([C:5]1[S:6][C:7]2[CH:13]=[C:12]([N+:14]([O-:16])=[O:15])[C:11](Cl)=[CH:10][C:8]=2[N:9]=1)([CH3:4])([CH3:3])[CH3:2].[CH3:18][CH:19]1[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]1.C(=O)([O-])[O-].[K+].[K+].O>CS(C)=O.C(Cl)(Cl)Cl>[C:1]([C:5]1[S:6][C:7]2[CH:13]=[C:12]([N+:14]([O-:16])=[O:15])[C:11]([N:22]3[CH2:23][CH2:24][CH:19]([CH3:18])[CH2:20][CH2:21]3)=[CH:10][C:8]=2[N:9]=1)([CH3:4])([CH3:3])[CH3:2]参加物
7
実験手順
A solution of 32,4 g of 2-tert-butyl-5-chloro-6-nitrobenzothiazole, (described in European patent application 85810418.5 published under No. 0175650) in 300 ml of dimethylsulphoxide, is stirred and heated at 140° for 6 hours with 12.8 g of 4-methylpiperidine and 35.8 g of anhydrous potassium carbonate, cooled and poured into water. The solid obtained is dissolved in chloroform and filtered through a silical gel column. The filtate is evaporated to give 2-tert-butyl-5-(4-methylpiperidin-1-yl)-6-nitrobenzothiazole melting at 116°-120°.
後処理
- temperaturecooled
- customThe solid obtained
- filtrationfiltered through a silical gel column
- customThe filtate is evaporated
出典と根拠
- ORDレコード
- ord-269df9c1e534472b9cb72738c8208fee
- 出典データセット
- uspto-grants-1993_09
- 特許番号
- US05246927
関連ノート
読み込み中…